This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)
|Treatment||Placebo, Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|
|Clinical Study Identifier||NCT04409509|
|Last Modified on||25 January 2021|
Select a piece of text and start making personal notes.
Congrats! You have your own personal workspace now.